Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
47.1 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 182.953 | 17.447 | 25.816 | 57.027 | 0 | 0 | 0 |
| Cost of Revenue
| 12.826 | 1.593 | 0.955 | 2.075 | 0.246 | 0.074 | 0.001 |
| Gross Profit
| 170.127 | 15.854 | 24.861 | 54.952 | -0.246 | -0.074 | -0.001 |
| Gross Profit Ratio
| 0.93 | 0.909 | 0.963 | 0.964 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 53.386 | 50.312 | 42.624 | 41.712 | 18.826 | 3.162 | 0.901 |
| General & Administrative Expenses
| 0 | 0 | 44.949 | 25.397 | 8.172 | 1.136 | 0.449 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 237.31 | 108.7 | 44.949 | 25.397 | 8.172 | 1.136 | 0.449 |
| Other Expenses
| 0 | 0 | 0.086 | -0.073 | 0 | 0 | 0 |
| Operating Expenses
| 290.696 | 159.012 | 87.573 | 67.109 | 26.998 | 4.298 | 1.35 |
| Operating Income
| -120.569 | -143.158 | -62.712 | -12.157 | -26.998 | -4.298 | -1.35 |
| Operating Income Ratio
| -0.659 | -8.205 | -2.429 | -0.213 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.015 | 7.265 | 0.617 | -1.615 | 0.188 | -0.371 | 0.032 |
| Income Before Tax
| -115.554 | -135.893 | -62.095 | -13.772 | -26.81 | -4.669 | -1.318 |
| Income Before Tax Ratio
| -0.632 | -7.789 | -2.405 | -0.241 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.004 | 0.055 | 0.001 | 0.001 | 0.001 |
| Net Income
| -115.554 | -135.893 | -62.091 | -13.827 | -26.811 | -4.67 | -1.319 |
| Net Income Ratio
| -0.632 | -7.789 | -2.405 | -0.242 | 0 | 0 | 0 |
| EPS
| -3.07 | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| EPS Diluted
| -3.07 | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| EBITDA
| -106.882 | -131.67 | -59.107 | -13.166 | -26.564 | -4.555 | -1.349 |
| EBITDA Ratio
| -0.584 | -7.547 | -2.29 | -0.186 | 0 | 0 | 0 |